SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.36+1.4%Nov 26 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Machaon who wrote (27970)2/7/1999 12:40:00 PM
From: Henry Niman  Read Replies (1) of 32384
 
Bob, the situation may be somewhat analogous to breast cancer treatment with Tamoxifen. The rationale behind the development of Tamoxifen was the observation that it acted like an anti-estrogen. It would bind to the estrogen receptor (ER) and block estrogen binding. Consequently, it was initially tested and approved for the treatment of ER+ breast cancer. However, it was subsequently observed to have an effect on ER- breast cancer also, and is now approved for the treatment of ER+ and ER- breast cancer.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News